Aquestive Therapeutics Readies $60 Million IPO
(WorldNews Health)

Quick Take Aquestive Therapeutics (AQST) intends to raise $60 million in an IPO of its common stock, according to an amended registration statement. The company is advancing a pipeline of treatment candidates for central nervous system disorders. AQST is using its manufacturing profits to defray development costs for its high-risk, high-reward CNS pipeline. Company & Technology The Warren, New Jersey-based pharmaceutical company was founded in 2004 as MonoSol Rx and is advancing a diverse pipeline of treatment for diseases such as Lennox-Gastaut syndrome and Acute Repetitive Seizures. Management is headed by CEO Keith J. Kendall, who has been with the firm since 2006 and was previously...